For the first time in 20 years, the Food and Drug Administration has approved a new pharmaceutical approach to treating pain. On January 31, the FDA approved Journavx as a non-opioid treatment for ...
Though long COVID, or post-acute sequelae of SARS-CoV-2 (PASC), is more common in adults than in kids, 1.3% of US children ...